Florida · 88275

Chromosome Analysis For Genetic Defects, Analyze 100-300 Cells in Florida

Florida Medicare Avg
$49.79
0% below national avg
National Medicare Avg
$50.02
All states combined
Billed Charge (FL)
$265.08
What providers submit
Est. Commercial (FL)
$117.00
National avg: $112.04
Est. Cash / Self-Pay (FL)
$110.24
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

224
Services in FL
9
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in Florida

Provider Medicare Services
Mayo Clinic Jacksonville $48.91 68
Quest Diagnostics Clinical... $50.17 37
Laboratory Corporation Of America $50.17 35
Quest Diagnostics Clinical... $50.17 24

Florida Pricing in Context

In Florida, CPT code 88275 (Chromosome Analysis For Genetic Defects, Analyze 100-300 Cells) carries an average Medicare payment of $49.79 — 0% below the national benchmark of $50.02. 9 providers across the state submitted claims for this procedure in 2023, performing 224 total services. Individual payments in FL ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Florida is $265.08, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Florida sits below the national Medicare average, commercial rates in the state may also run lower than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Genetic/Molecular Test procedures, the estimated commercial insurance price in Florida lands near $117.00, with self-pay cash prices typically around $110.24. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Chromosome Analysis For Genetic Defects, Analyze 100-300 Cells cost in Florida?

The average Medicare payment for Chromosome Analysis For Genetic Defects, Analyze 100-300 Cells in Florida is $49.79, which is 0% below the national average of $50.02. Providers in FL typically bill $265.08 for this procedure.

What does Chromosome Analysis For Genetic Defects, Analyze 100-300 Cells cost with insurance in Florida?

With commercial insurance in Florida, Chromosome Analysis For Genetic Defects, Analyze 100-300 Cells costs an estimated $117.00. Without insurance, the estimated cash price is $110.24. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Chromosome Analysis For Genetic Defects, Analyze 100-300 Cells in Florida?

9 providers in Florida billed Medicare for Chromosome Analysis For Genetic Defects, Analyze 100-300 Cells in 2023, performing 224 total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Chromosome Analysis For Genetic Defects, Analyze 100-300 Cells cheaper in Florida than the national average?

Yes — Chromosome Analysis For Genetic Defects, Analyze 100-300 Cells costs 0% below the national average in Florida. The state average Medicare payment is $49.79 compared to $50.02 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial